Hiroko Nakajima

2.9k total citations
55 papers, 1.3k citations indexed

About

Hiroko Nakajima is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Hiroko Nakajima has authored 55 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 25 papers in Immunology and 23 papers in Oncology. Recurrent topics in Hiroko Nakajima's work include Renal and related cancers (30 papers), Immunotherapy and Immune Responses (21 papers) and CAR-T cell therapy research (20 papers). Hiroko Nakajima is often cited by papers focused on Renal and related cancers (30 papers), Immunotherapy and Immune Responses (21 papers) and CAR-T cell therapy research (20 papers). Hiroko Nakajima collaborates with scholars based in Japan, Australia and United States. Hiroko Nakajima's co-authors include Haruo Sugiyama, Akihiro Tsuboi, Yoshitaka Oka, Yusuke Oji, Sumiyuki Nishida, Naoki Hosen, Fumihiro Fujiki, Shigeru Matsukura, Masahito Uchihashi and Ichiro Kawase and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Hiroko Nakajima

54 papers receiving 1.2k citations

Peers

Countries citing papers authored by Hiroko Nakajima

Since Specialization

Citations

This map shows the geographic impact of Hiroko Nakajima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroko Nakajima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroko Nakajima more than expected).

Fields of papers citing papers by Hiroko Nakajima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroko Nakajima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroko Nakajima. The network helps show where Hiroko Nakajima may publish in the future.

Co-authorship network of co-authors of Hiroko Nakajima

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroko Nakajima. A scholar is included among the top collaborators of Hiroko Nakajima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroko Nakajima. Hiroko Nakajima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia 2023 ·BMC Cancer ·(unknown), Yoshiko Hashii, Hiroko Nakajima, Fumihiro Fujiki, Soyoko Morimoto, Jun Nakata, Toshiro Shirakawa, Takane Katayama, Akihiro Tsuboi, Keiichi Ozono	5
2	Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs 2023 ·Cancer Immunology Immunotherapy ·Fumihiro Fujiki, Soyoko Morimoto, (unknown), (unknown), (unknown), (unknown), Kento Inoue, (unknown), Hiroko Nakajima, Jun Nakata, Sumiyuki Nishida, Akihiro Tsuboi, Yoshitaka Oka, Yusuke Oji, Shinji Sogo, Haruo Sugiyama	1
3	An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia 2022 ·Cancer Immunology Immunotherapy ·Natsuki Nakagawa, Yoshiko Hashii, Hisako Kayama, Ryu Okumura, Hiroko Nakajima, (unknown), Soyoko Morimoto, Fumihiro Fujiki, Jun Nakata, Toshiro Shirakawa, Takane Katayama, Kiyoshi Takeda, Akihiro Tsuboi, Keiichi Ozono	14
4	T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy 2022 ·Frontiers in Immunology ·Fumihiro Fujiki, Soyoko Morimoto, (unknown), (unknown), (unknown), (unknown), (unknown), Ayako Isotani, Masahito Ikawa, Sumiyuki Nishida, Hiroko Nakajima, Akihiro Tsuboi, Yoshitaka Oka, Jun Nakata, Naoki Hosen, Atsushi Kumanogoh, Yusuke Oji, Haruo Sugiyama	8
5	Imaging Assessment of Tumor Response in the Era of Immunotherapy 2021 ·Diagnostics ·Jun Nakata, Kayako Isohashi, Yoshitaka Oka, Hiroko Nakajima, Soyoko Morimoto, Fumihiro Fujiki, Yusuke Oji, Akihiro Tsuboi, Atsushi Kumanogoh, Naoya Hashimoto, Jun Hatazawa, Haruo Sugiyama	7
6	Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides 2020 ·Cancer Immunology Immunotherapy ·Fumihiro Fujiki, Akihiro Tsuboi, Soyoko Morimoto, Naoya Hashimoto, (unknown), Hiroko Nakajima, Jun Nakata, Sumiyuki Nishida, Kana Hasegawa, Naoki Hosen, Yoshitaka Oka, Yusuke Oji, Shinji Sogo, Haruo Sugiyama	7
7	A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma 2018 ·Cancer Immunology Immunotherapy ·Akihiro Tsuboi, Naoya Hashimoto, Fumihiro Fujiki, Soyoko Morimoto, Naoki Kagawa, Hiroko Nakajima, Naoki Hosen, Sumiyuki Nishida, Jun Nakata, Satoshi Morita, Junichi Sakamoto, Yusuke Oji, Yoshitaka Oka, Haruo Sugiyama	43
8	Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8 + T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells 2016 ·Clinical Immunology ·Jordana Grazziela Alves Coelho-dos-Reis, Jing Huang, Tiffany Tsao, Felipe V. Pereira, (unknown), Hiroko Nakajima, Haruo Sugiyama, Moriya Tsuji	18
9	An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells 2016 ·Journal of Immunotherapy ·Kenta Kondo, Fumihiro Fujiki, Hiroko Nakajima, (unknown), Soyoko Morimoto, Naoya Tatsumi, Sumiyuki Nishida, Jun Nakata, Yoshitaka Oka, Akihiro Tsuboi, Naoki Hosen, Yusuke Oji, Haruo Sugiyama	2
10	Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response 2015 ·Cancer Immunology Immunotherapy ·Naoya Hashimoto, Akihiro Tsuboi, Naoki Kagawa, Yasuyoshi Chiba, Shuichi Izumoto, Manabu Kinoshita, Noriyuki Kijima, Yoshitaka Oka, Soyoko Morimoto, Hiroko Nakajima, Satoshi Morita, Junichi Sakamoto, Sumiyuki Nishida, Naoki Hosen, Yusuke Oji, Norio Arita, Toshiki Yoshimine, Haruo Sugiyama	34
11	An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells 2015 ·PLoS ONE ·Kana Hasegawa, Satomi Tanaka, Fumihiro Fujiki, Soyoko Morimoto, Hiroko Nakajima, Naoya Tatsumi, Jun Nakata, S Takashima, Sumiyuki Nishida, Akihiro Tsuboi, Yoshitaka Oka, Yusuke Oji, Atsushi Kumanogoh, Haruo Sugiyama, Naoki Hosen	13
12	Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms 2015 ·PLoS ONE ·Naoya Tatsumi, (unknown), Hiroyuki Sakamoto, (unknown), (unknown), (unknown), Mari Fukuda, Akihide Matsumura, Seiji Hayashi, Soyoko Morimoto, Jun Nakata, Fumihiro Fujiki, Sumiyuki Nishida, Hiroko Nakajima, Akihiro Tsuboi, Yoshitaka Oka, Naoki Hosen, Haruo Sugiyama, Yusuke Oji	9
13	Functional human Th17 clones with WT1-specific helper activity 2012 ·Cancer Immunology Immunotherapy ·Sho Tachino, Fumihiro Fujiki, Yoshitaka Oka, Akihiro Tsuboi, Soyoko Morimoto, Yu‐Hung Lin, (unknown), Kenta Kondo, Hiroko Nakajima, Sumiyuki Nishida, Naoki Hosen, Yusuke Oji, Atsushi Kumanogoh, Haruo Sugiyama	1
14	WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient 2010 ·European Journal Of Haematology ·Yusuke Oji, Yoshitaka Oka, Sumiyuki Nishida, Akihiro Tsuboi, Manabu Kawakami, Toshiaki Shirakata, (unknown), (unknown), Hiroko Nakajima, Miwako Narita, Masuhiro Takahashi, Satoshi Morita, Junichi Sakamoto, Toshio Tanaka, Ichiro Kawase, Naoki Hosen, Haruo Sugiyama	28
15	WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide 2009 ·Anti-Cancer Agents in Medicinal Chemistry ·Yoshitaka Oka, Akihiro Tsuboi, Fumihiro Fujiki, Zheyu Li, Hiroko Nakajima, Naoki Hosen, Toshiaki Shirakata, Sumiyuki Nishida, Yusuke Oji, Ichiro Kawase, Haruo Sugiyama	17
16	Biased usage of BV gene families of T‐cell receptors of WT1 (Wilms’ tumor gene)‐specific CD8⁺ T cells in patients with myeloid malignancies 2009 ·Cancer Science ·(unknown), Manabu Kawakami, Yoshitaka Oka, Akihiro Tsuboi, Takamasa Katagiri, (unknown), Sumiyuki Nishida, Toshiaki Shirakata, Naoki Hosen, Fumihiro Fujiki, (unknown), Hiroko Nakajima, Yusuke Oji, Yoshinobu Kanda, Ichiro Kawase, Haruo Sugiyama	14
17	Clinical and Immunologic Responses to Very Low-Dose Vaccination with WT1 Peptide (5 μg/Body) in a Patient with Chronic Myelomonocytic Leukemia 2007 ·International Journal of Hematology ·Manabu Kawakami, Yoshitaka Oka, Akihiro Tsuboi, Yukie Harada, Olga A. Elisseeva, Yoshio Furukawa, Machiko Tsukaguchi, Toshiaki Shirakata, Sumiyuki Nishida, Hiroko Nakajima, Satoshi Morita, Junichi Sakamoto, Ichiro Kawase, Yusuke Oji, Haruo Sugiyama	29
18	Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis 2003 ·International Journal of Hematology ·Yoshitaka Oka, Akihiro Tsuboi, Masaki Murakami, Manabu Hirai, Nobuhiko Tominaga, Hiroko Nakajima, Olga A. Elisseeva, Tomoki Masuda, Akiko Nakano, Manabu Kawakami, Yusuke Oji, Kazuhiro Ikegame, Naoki Hosen, Keiko Udaka, Masaki Yasukawa, Hiroyasu Ogawa, Ichiro Kawase, Haruo Sugiyama	90
19	Negative strand of hepatitis C virus RNA in the liver of patients with chronic hepatitis C after interferon treatment 1997 ·Journal of Gastroenterology and Hepatology ·Masahiko Tomimatsu, Hitoshi Endou, Haruki Takahashi, (unknown), Yoshikazu Kato, (unknown), Hiroko Nakajima, Akira Okano, Haruki Mori, Hisashi Hisatomi	9
20	Precursor-product relationship between chicken vitellogenin and the yolk proteins: the 40 kDa yolk plasma glycoprotein is derived from the C-terminal cysteine-rich domain of vitellogenin II 1995 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Jun‐ichi Yamamura, Takahiro Adachi, Naohito Aoki, Hiroko Nakajima, Ryô Nakamura, Tsukasa Matsuda	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact